Document:

Exhibit 10.22

Exhibit 10.22

File No. 97-098L

April 12, 2005

David Karp

Chief Financial Officer

Chemokine Therapeutics Corp.

2386 East Mall – Suite 208

Vancouver, BC V6T 1Z3

Canada

VIA CAMPUS MAIL

Dear Mr. Karp,

Re: Amendment to License Agreement between UBC and Chemokine Therapeutics Corporation dated September 22, 1999 (the “License”).

This letter agreement is to amend the subject of the License.  The parties hereby agree to amend the License by making the following changes:

1. Change section 11.4(c) so that it shall now read:

(c)

commence Phase II clinical trials by December 31, 2005.  The Licensee covenants to notify the University, in writing, within 15 days of the commencement of Phase II clinical trials;”

2. Change section 12.2 so that it shall now read:

12.2

The Licensee will complete and deliver to UBC:

(a)

within 30 days of each and every Royalty Due Date, a completed Payment Report in the form attached as Schedule "C", (or an amended form as required by UBC from time to time) together with the royalty payable under this Agreement. A separate Payment Report shall be prepared and delivered for each sublicense , including an accounting statement setting out in detail how the amount of sublicensing revenue was determined and identifying each sublicensee and the location of the business of each sublicensee. The first Payment Report will be submitted within 30 days of the first Royalty Due Date after the receipt of the first Revenue or sublicensing revenue, and thereafter a Payment Report shall be delivered every three months regardless of whether any Revenue or sublicensing revenue were received in the preceding period; and

(b)

on or before January 1 of each year during the term of the license, starting on January 1, 2006, an Annual Report in the form attached as Schedule “D” (or an amended form as required by UBC from time to time).

Schedules C and D are attached to the end of this document.

All other terms and conditions of the Agreement will remain in full force and effect and shall continue for the duration of the Agreement. This letter, upon execution by both parties, shall form part of the Agreement and the two documents shall be read together. If the foregoing amendment is satisfactory, please have this letter executed on behalf of Chemokine Therapeutics Corporation in the space provided.

Both parties agree that this agreement may be executed in counterpart, and may be delivered by fax.

Yours sincerely,

/s/ David Jones

David P. Jones, Associate Director

UBC Industry Liaison Office

	Agreed and Accepted by Chemokine

	 	 
	Therapeutics Corporation

	 /s/ Hassan Salari

	Date: April 13, 2005

SCHEDULE “C”

	 	Payment Report for the Period  

	 

Instructions for Completing this Report

Please fill out each section in full, identifying the Royalty Summary Table the unit sales and geographical sales areas.  If the license with UBC involves several product lines, please prepare a separate Summary Table for each product line.  For licenses involving sublicensing revenue, please prepare an additional report for each sublicense.

PLEASE NOTE:  An average interest rate of 12.68% per annum, calculated annually not in advance will be assessed against all payments in arrears.

	Licensee

	 	Agreement #

	97-098L

	UBC ID #

	97-098

	(or sublicensee)

	 	 	 	 	 

UBC Technology

Human Stromal-Derived Factor 1 Peptide Agonist

Report Type (check one and complete as appropriate)

	Single Product Line

	 	Product Line Trade Name

	 

	Multiple Products

	 	Page       Of       Product Line Trade Name

	 

	Sublicense Report

	 	Page       Of       

	 

Payments this Quarter (please complete separate tables for multiple product lines) Royalties on Product Sales

	Country

	Units Sold

	Unit Price (domestic currency)

	Gross sales

	Less Allow-ances*

	Net Sales

	Royalty

Rate

	Conversion Rate (to Canadian $)

	Period Royalty Amount (Canadian $)

	This yr

	Last yr

	Canada

US

Europe

(specify

countries)

Other

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	Total Product Royalties

	 	 
	Additional Payments (complete all that apply)

	 	 	 	 	 
	Minimum Royalty Fee

	 	 	 	 	Amount

	 	 
	Milestone Payment

	 	 	 	 	Amount

	 	 
	Annual License Maintenance Fee

	 	 	 	 	Amount

	 	 
	 	 	 	 	This Year

	This Year

	 	 	 	Total Payments for Period

	 	 

*Please indicate the reasons for returns or other allowances, if significant.  Please note any unusual occurrences that affected royalty amounts during the period.

Prepared by

_________________  Date

  Dd/mm/yy

  Phone

________________

I____________________ (print name), _________________________ (title) hereby certify the foregoing information as true and correct.

______________________________________________________________________________________

Signature

Date Signed

Schedule “D”

UBC License Agreement Annual Report

The information to be completed below shall constitute the annual report required pursuant to the UBC License Agreement.  Any information or documents provided by the Licensee in this report shall not be interpreted as affecting the express rights and obligations of the Licensee contained in the License Agreement.  This report is in addition to the Payment Report o accompany each royalty payment.

Date of Report:

______________

Person Preparing This Report:

____________________

Name of Licensee:

Chemokine

UBC File Number:

97-098L

Therapeutics Corp. 

Jurisdiction of Corporation:

____________________________ Head Office

_____________________

Address:

Contact Person for Company

________________________________________________________________

Licensed Technology:

Human Stromal-Derived Factor 1 Peptide Agonist

Telephone Number:

__________________

Email Address:

____________________________

1.

Please provide a brief report on the status of development of the UBC Technology, progress on creating a commercial Product or subsequent marketing of the Product as appropriate.

_____________________________________________________________________

_____________________________________________________________________

2.

Has the Licensee filed any patent applications for modifications or improvements relating to the original UBC Technology?  Please provide details, and attach copies of all relevant documents.

_____________________________________________________________________

_____________________________________________________________________

3.

Has the Licensee become aware of any potential 3rd party infringing on the UBC patents or related intellectual property?  If so please provide details and outline what the Licensee is doing about this.

_____________________________________________________________________

_____________________________________________________________________

4.

Has the Licensee met any milestone or other performance objectives in the past year as set forth in the license agreement?  Please outline the past year’s accomplishments.

_____________________________________________________________________

_____________________________________________________________________

5.

Does the Licensee expect to meet any milestone or performance objective in the coming year as set forth in the license agreement?  If so please provide details.

_____________________________________________________________________

_____________________________________________________________________

6.

If applicable, has the Licensee granted sublicenses to 3rd parties and if so have copies of the sublicense agreement been provided to the Technology Manager at UBC?  If not, please enclose a copy of each sublicense agreement.

_____________________________________________________________________

_____________________________________________________________________

7.

Has the licensee made any sales in the last 12 months?  Yes ______ No _______

If so please submit a completed Royalty Payment Report.

a) Date of sales of Products utilizing the Technology;

b) Date of any clinical trials.

______________________________________________________

______________________________________________________

8.

Does your company have public liability insurance?  If so, please attach a copy of the insurance policy naming UBC as insured as required by the License Agreement.

______________________________________________________

______________________________________________________

9.

Please provide the Licensee’s estimate or projection of gross sales revenue for products based on the UBC Technology for the next 12 months by licensee and any sub-licensee.

______________________________________________________

______________________________________________________

10.

Is there any other information relating to this License that you think we should be aware of?  Please summarize them below or contact us directly.

______________________________________________________

______________________________________________________

Prepared by

_____________________  Date

 Dd/mm/yy

  Phone

__________________

I ____________________ (print name), of ________________ (title) hereby certify the foregoing information as true and correct.

_________________________________________________________

Signature

Date Signed

Once completed, please submit this report to:

Managing Director c/o Licensing Compliance Officer

University – Industry Liaison Office

#103 – 6190 Agronomy Road

Vancouver, BC

V6T 1Z3Treasury Order

RUBINCON VENTURES INC.

c/o Suite 2410, 650 West Georgia Street

Vancouver, BC Canada V6B 4N7

 (the "Company")

 

 

April 20, 2006

Mr. Guy Peckham

1203-1005 Beach Avenue 

Vancouver, British Columbia 

Canada

 

Dear Sir:

Re: Appointment as President of Rubincon Ventures Inc. (the "Company")

This letter is written to confirm your position as President of the Company and to further confirm the terms of this appointment.

The terms of your appointment are as follows:

1.  You shall receive a monthly salary of $5,000 retroactive to November 7, 2005; and

2.  The Company may, at any time without cause or reason, terminate you in your position as President provided that you receive thirty (30) days' notice.

Please confirm your appointment and the terms described above by executing this letter below.

Yours truly,

RUBINCON VENTURES INC.

 

/s/ Guy Peckham______ 

      Guy Peckham

The terms above are hereby read, understood, acknowledged and accepted this 20th day of April, 2006

/s/ Guy Peckham,______

GUY PECKHAM

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}]]